In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

Allurion Technologies (ALUR) announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, ...

Allurion Technologies, Inc. ("Allurion" or the "Company") , a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French ...

Allurion Technologies, Inc. (ALUR) closed the last trading session at $6.04, gaining 58.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.